Coya Therapeutics, Inc. Common Stock (COYA) is a publicly traded Healthcare sector company. As of May 21, 2026, COYA trades at $4.64 with a market cap of $115.41M and a P/E ratio of -4.62. COYA moved +0.77% today. Year to date, COYA is -13.81%; over the trailing twelve months it is -21.16%. Its 52-week range spans $3.71 to $10.24. Analyst consensus is strong buy with an average price target of $16.25. Rallies surfaces COYA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Coya Therapeutics Secures FDA Fast Track for COYA-302 ALS Therapy: Coya Therapeutics received U.S. FDA Fast Track designation on May 12, 2026 for its lead candidate COYA-302 in amyotrophic lateral sclerosis. The designation grants rolling review and potential priority review benefits, potentially accelerating COYA-302’s clinical development and enhancing Coya’s valuation in the $1.5 billion ALS treatment market.
| Metric | Value |
|---|---|
| Price | $4.64 |
| Market Cap | $115.41M |
| P/E Ratio | -4.62 |
| EPS | $-0.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.24 |
| 52-Week Low | $3.71 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.55M |
| Net Income | $-14.88M |
| Gross Margin | 0.00% |
4 analysts cover COYA: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.25.